Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pramoda Jayasinghe

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Current Medical Research and Opinion|April 28, 2025
Assessing the symptom control provided by ravulizumab or efgartigimod in myasthenia gravis: an evaluation of the patient experience of two different treatment approachesChristopher A Scheiner, Masayuki Masuda, Tim Hagenacker, et al.
The Journal of Headache and Pain|January 3, 2025
Reduction of pain and functional disability over time in patients treated with zavegepant: a post-hoc analysis of the BHV3500-301 phase 3 randomized controlled trialLauren Powell, Fiona O'Sullivan, Pramoda Jayasinghe, et al.
Advances in Therapy|July 13, 2026
Estimating Utility Values Using the DMD-QoL: A Disease-Specific Preference-Based Measure for Duchenne Muscular Dystrophy (DMD)Andrea Bever, Shelagh M Szabo, Pramoda Jayasinghe, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Current Medical Research and Opinion|April 28, 2025
Assessing the symptom control provided by ravulizumab or efgartigimod in myasthenia gravis: an evaluation of the patient experience of two different treatment approachesChristopher A Scheiner, Masayuki Masuda, Tim Hagenacker, et al.
The Journal of Headache and Pain|January 3, 2025
Reduction of pain and functional disability over time in patients treated with zavegepant: a post-hoc analysis of the BHV3500-301 phase 3 randomized controlled trialLauren Powell, Fiona O'Sullivan, Pramoda Jayasinghe, et al.
Advances in Therapy|July 13, 2026
Estimating Utility Values Using the DMD-QoL: A Disease-Specific Preference-Based Measure for Duchenne Muscular Dystrophy (DMD)Andrea Bever, Shelagh M Szabo, Pramoda Jayasinghe, et al.
Pageof 1